The verdict
Our read at a glance.
Whether PNC-27's preclinical cancer-cell-killing in the lab supports the anticancer claims made for it, given there are no human trials.
- The signal
- Laboratory and animal studies report that PNC-27 can kill cancer cells, apparently by disrupting their membranes while sparing normal cells. There are no published human trials, so its safety and benefit in people are unknown. It is not approved for any use.
- The unknown
- Whether any of the laboratory anticancer effects occur in people, and whether it is safe, neither of which has been tested in human trials.
- Our read
- A striking laboratory anticancer claim with no human evidence, not a treatment. PNC-27's cell and animal data are interesting, but with no human trials it is unproven, and promoting it to people with cancer is a serious concern.
The mechanism
How it works.
PNC-27 is a synthetic peptide that fuses a fragment of the p53 tumor-suppressor protein to a short membrane-penetrating sequence. The proposed mechanism is that the p53 portion binds HDM-2, a protein that sits on the surface of cancer cells in unusually high amounts, and the attached segment then forms pores in the membrane that rupture the cell, while normal cells with little surface HDM-2 are spared. This rests entirely on cell-culture and rodent work and has not been shown to kill tumors safely in people.
Safety & regulatory boundary
The consequential part.
PNC-27 is not an approved drug and has not been tested in published human trials. It is sold as a research chemical, where identity and quality are uncertain, and it is sometimes promoted to people with cancer. Laboratory findings do not establish a human cancer treatment, and using unproven products in place of real cancer care is dangerous.
What's next
What we're watching.
Whether it ever enters controlled human trials, and any safety or efficacy data if it does.
Context
Why this is discussed.
PNC-27 is promoted as a peptide that selectively destroys cancer cells, a striking laboratory claim that draws interest even though it has not been tested in people.
The evidence base
12 cited references.
Indexed literature (PubMed)12
Sarafraz-Yazdi E et al. · Biomedicines · 2022
Krzesaj P et al. · Ann Clin Lab Sci · 2024
Sookraj KA et al. · Cancer Chemother Pharmacol · 2010
Rahmani R et al. · Iran J Basic Med Sci · 2022
Krzesaj PK et al. · Ann Clin Lab Sci · 2025
Davitt K et al. · Ann Clin Lab Sci · 2014
Alagkiozidis I et al. · Ann Clin Lab Sci · 2017
Sarafraz-Yazdi E et al. · Proc Natl Acad Sci U S A · 2010
Darban SA et al. · Nanomedicine (Lond) · 2017
Soriano-Correa C et al. · J Mol Graph Model · 2023
Pincus MR et al. · Biomedicines · 2024
Thadi A et al. · Anticancer Res · 2020
Keep reading